Join us for an Investor Event with TScan Therapeutics on the Company’s clinical plans to treat a variety of solid tumors with multiplexed TCR-T cell therapy. Harnessing ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, TScan looks to provide customized multiplexed therapies unique to each patient’s tumor.

The TScan Therapeutics leadership team will discuss its current solid tumor program pipeline, in addition to the current treatment landscape and potential future directions.

A live Q&A session will follow the formal presentations.